Clinical trials: Cancer Disease Progression, active
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Castration-Resistant Prostate Cancer
AI Multimodal Model for Predicting CRPC Progression Risk
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease.
- Trial name
- AI-MM_CPRC (NCT07658573)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Colorectal Cancer
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.
- Trial name
- NCT06441565
- Testing
- Fruquintinib, Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Metastatic Cancer
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (> 6 months) and displaying disease progression.
- Trial name
- RESTO-IMMUNO (NCT06363773)
- Testing
- Stereotactic Radiotherapy
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Elsan
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Progression
A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
- Trial name
- NCT04905056
- Testing
- Ablation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+)…
- Trial name
- NCT06123494
- Testing
- SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Urothelial Cancer
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
- Trial name
- NCT07106762
- Testing
- Iza-bren, Cisplatin, Gemcitabine
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Atherosclerosis
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
This study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ICI. The study will be conducted at various sites across Australia.
- Trial name
- SOCRATES (NCT05180942)
- Where
- 12 sites in Australia
- Volunteers
- 130 people
- Sponsor
- Monash University
Breast Cancer, Lung Metastasis
Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
This is a proof-of-concept clinical trial focused on exploring whether hyperbaric oxygen therapy (HBOT) can inhibit the progression of lung metastasis in breast cancer patients.
- Conditions
- Breast Cancer, Lung Metastasis, Hyperbaric Oxygen Therapy
- Trial name
- HBOIBCLM (NCT07514728)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jinan Central Hospital
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
HER2-positive Breast Cancer
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer…
- Trial name
- TUC-TOC (NCT05955170)
- Testing
- Tucatinib in Combination of Oral VP16 and trastuzumab
- Where
- 13 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut Curie
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral Resection of Bladder Tumor
- Trial name
- NCT07589413
- Testing
- Measurement of Intraoperative Irrigation Fluid Absorption and Perioperative cfDNA Profiling
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhiping Wang
Renal Cell Carcinoma (RCC)
Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance
This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with…
- Trial name
- NCT07714018
- Testing
- Intermittent Fasting, Continuous Energy Restriction (CER)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after progression on trastuzumab are enrolled and…
- Trial name
- NCT04736589
- Testing
- Inetetamab, Rapamycin, Pyrotinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking Union Medical College
Rectal Cancer, Neoadjuvant Therapy
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Background There is currently no reliable means to restage rectal cancers after neoadjuvant chemoradiation. There are still no reliable methods to identify patients with pCR before radical surgery.
- Conditions
- Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
- Trial name
- BIOPSY (NCT04743102)
- Testing
- multi-points and full-thickness Biopsy, traditional cCR
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Beijing Chao Yang Hospital
KLF4 Methylation, Epigenetic
KLF4 Epigenetic Modulation
The study investigates the epigenetic regulation of KLF4 during the progression from colorectal polyps to adenomas and carcinomas.
- Trial name
- POLYEP (NCT07901335)
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines